Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 20/20 | 0.89 |
| ▸ | TNKS | O95271 | 3/20 | 0.89 |
| ▸ | TNKS2 | Q9H2K2 | 3/20 | 0.89 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2474012 | 1.00 | PARP1 (0.89) | PARP1TNKSTNKS2 | |
| SCHEMBL15204765 | 0.97 | PARP1 (0.85) | PARP1TNKSTNKS2 | |
| SCHEMBL22829810 | 0.94 | PARP1 (1.00) | PARP1TNKSTNKS2 | |
| SCHEMBL28732598 | 0.93 | PARP1 (0.79) | PARP1TNKSTNKS2 | |
| SCHEMBL22829832 | 0.91 | PARP1 (1.00) | PARP1TNKSTNKS2 | |
| SCHEMBL22829834 | 0.91 | PARP1 (1.00) | PARP1TNKSTNKS2 | |
| SCHEMBL15846129 | 0.91 | PARP1 (0.79) | PARP1TNKSTNKS2 | |
| SCHEMBL22829824 | 0.91 | PARP1 (1.00) | PARP1TNKSTNKS2 | |
| SCHEMBL19569971 | 0.90 | PARP1 (0.90) | PARP1TNKSTNKS2 | |
| SCHEMBL22829772 | 0.89 | PARP1 (0.94) | PARP1TNKSTNKS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250270212-A1 | CHIMERIC COMPOUNDS USEFUL IN TREATING DISEASES | PADARN THERAPEUTICS INC (US) | 2025-08-28 | — | — | US | disclosed |
| EP-4416151-A1 | CHIMERIC COMPOUNDS USEFUL IN TREATING DISEASES | Padarn Therapeutics, Inc. (US) | 2024-08-21 | — | — | EP | disclosed |
| CN-115873014-B | Controllable proteolytic targeted chimera and application thereof | 中国药科大学 | 2024-08-20 | — | — | CN | disclosed |
| CN-115991880-B | Dendrimer PAMAM-G5-TCO and preparation method and application thereof | 中国药科大学 | 2024-03-19 | — | — | CN | disclosed |
| CN-115991880-A | Dendrimer PAMAM-G5-TCO and preparation method and application thereof | 中国药科大学 | 2023-04-21 | — | — | CN | disclosed |
| WO-2023064164-A1 | CHIMERIC COMPOUNDS USEFUL IN TREATING DISEASES | PADARN THERAPEUTICS, INC. (US) | 2023-04-20 | — | — | WO | disclosed |
| CN-115873014-A | Controllable proteolysis targeting chimera and application thereof | 中国药科大学 | 2023-03-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250270212-A1 | CHIMERIC COMPOUNDS USEFUL IN TREATING DISEASES | WEE1, WEE2, PARP1 | PARP1 3/4885TNKS 48/4885TNKS2 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.